Detection for predictive factors of estrogen addition and depletion therapy in endocrine therapy-resistant breast cancer
Project/Area Number |
26461952
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
General surgery
|
Research Institution | Kyoto Prefectural University of Medicine |
Principal Investigator |
Omoto Yoko 京都府立医科大学, 医学(系)研究科(研究院), 客員講師 (80642561)
|
Co-Investigator(Kenkyū-buntansha) |
岩瀬 弘敬 熊本大学, 大学院生命科学研究部(医), 教授 (40211065)
山本 豊 熊本大学, 大学院生命科学研究部(医), 准教授 (20398217)
田口 哲也 京都府立医科大学, 医学(系)研究科(研究院), 教授 (80243260)
|
Project Period (FY) |
2014-04-01 – 2017-03-31
|
Project Status |
Completed (Fiscal Year 2016)
|
Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
Keywords | エストロゲンレセプター / 乳癌 / 内分泌療法 / ホルモン療法 / ホルモン依存性 / 内分泌療法耐性乳癌 / エストロゲン療法 |
Outline of Final Research Achievements |
The purpose of this study is to detect predictive factors of endocrine therapy sensitivity of breast cancer. A specimen from estrogen receptor (ER) -positive recurrent breast cancer patient who became aromatase inhibitor (AI) resistant during long-term AI treatment was applied for this study. It was suggested that the non-genomic pathway was involved in the difference in response of AI treatment. Furthermore, we succeeded in pointing out that early ER genetic change is involved in a change in susceptibility to hormonal therapy and we also demonstrated that the blood sample is also possible to use for monitoring of this early gene mutation. Our finding has a possibility to provide a great benefit to breast cancer patients to predict endocrine therapy responsiveness.
|
Report
(4 results)
Research Products
(10 results)